BR112022009799A2 - Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23 - Google Patents
Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23Info
- Publication number
- BR112022009799A2 BR112022009799A2 BR112022009799A BR112022009799A BR112022009799A2 BR 112022009799 A2 BR112022009799 A2 BR 112022009799A2 BR 112022009799 A BR112022009799 A BR 112022009799A BR 112022009799 A BR112022009799 A BR 112022009799A BR 112022009799 A2 BR112022009799 A2 BR 112022009799A2
- Authority
- BR
- Brazil
- Prior art keywords
- variable domains
- polypeptides
- tnfalfa
- single variable
- immunoglobulin targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944619P | 2019-12-06 | 2019-12-06 | |
| EP20305056 | 2020-01-23 | ||
| EP20000090 | 2020-02-28 | ||
| EP20305216 | 2020-03-02 | ||
| PCT/EP2020/084430 WO2021110816A1 (en) | 2019-12-06 | 2020-12-03 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009799A2 true BR112022009799A2 (pt) | 2022-08-16 |
Family
ID=73642903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009799A BR112022009799A2 (pt) | 2019-12-06 | 2020-12-03 | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20210188963A1 (https=) |
| EP (1) | EP4069733A1 (https=) |
| JP (1) | JP7657797B2 (https=) |
| KR (1) | KR20220122652A (https=) |
| CN (1) | CN114981300B (https=) |
| AU (1) | AU2020396204A1 (https=) |
| BR (1) | BR112022009799A2 (https=) |
| CA (1) | CA3163877A1 (https=) |
| CO (1) | CO2022009239A2 (https=) |
| IL (1) | IL293561A (https=) |
| MX (1) | MX2022006880A (https=) |
| PH (1) | PH12022551214A1 (https=) |
| TW (1) | TW202134269A (https=) |
| WO (1) | WO2021110816A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| EP4707303A2 (en) | 2014-05-16 | 2026-03-11 | Ablynx NV | Improved immunoglobulin variable domains |
| WO2020144164A1 (en) | 2019-01-07 | 2020-07-16 | Bactolife Aps | Pathogen binding proteins |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| IL293561A (en) | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23 |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| EP4438614A1 (en) | 2023-03-31 | 2024-10-02 | Sanofi | Methods for purifying heteromultimeric antibodies |
| TW202542180A (zh) * | 2023-12-22 | 2025-11-01 | 比利時商艾伯霖克斯公司 | 用於位點特異性胺軛合的基於蛋白質的載體 |
| CN118687298A (zh) | 2024-07-29 | 2024-09-24 | 上海原能细胞生物低温设备有限公司 | 一种立式低温存储冰箱 |
| CN119371530B (zh) * | 2024-11-06 | 2025-05-20 | 北京科道博济生物科技有限公司 | 一种靶向il-23a的纳米抗体及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| WO2004041863A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| EP2650311A3 (en) * | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2723771B1 (en) | 2011-06-23 | 2019-09-11 | Ablynx NV | Serum albumin binding proteins |
| EP4707303A2 (en) * | 2014-05-16 | 2026-03-11 | Ablynx NV | Improved immunoglobulin variable domains |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| EP3365371B1 (en) * | 2015-10-22 | 2025-10-08 | Ablynx NV | Gitr agonists |
| NO2768984T3 (https=) | 2015-11-12 | 2018-06-09 | ||
| LT3374392T (lt) | 2015-11-13 | 2022-01-25 | Ablynx Nv | Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| JP7540877B2 (ja) * | 2016-02-12 | 2024-08-27 | アブリンクス エン．ヴェー． | 免疫グロブリン単一可変ドメインの生成方法 |
| RU2022101604A (ru) | 2016-12-07 | 2022-03-29 | Аблинкс Нв | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином |
| IL267897B2 (en) | 2017-01-17 | 2025-02-01 | Ablynx Nv | Improved serum albumin binders |
| JP7219220B2 (ja) | 2017-01-17 | 2023-02-07 | アブリンクス エン．ヴェー． | 改善された血清アルブミン結合剤 |
| AR112341A1 (es) | 2017-08-02 | 2019-10-16 | Lilly Co Eli | ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG |
| IL293561A (en) | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23 |
-
2020
- 2020-12-03 IL IL293561A patent/IL293561A/en unknown
- 2020-12-03 CA CA3163877A patent/CA3163877A1/en active Pending
- 2020-12-03 PH PH1/2022/551214A patent/PH12022551214A1/en unknown
- 2020-12-03 MX MX2022006880A patent/MX2022006880A/es unknown
- 2020-12-03 AU AU2020396204A patent/AU2020396204A1/en not_active Abandoned
- 2020-12-03 BR BR112022009799A patent/BR112022009799A2/pt not_active Application Discontinuation
- 2020-12-03 JP JP2022533410A patent/JP7657797B2/ja active Active
- 2020-12-03 CN CN202080083442.0A patent/CN114981300B/zh active Active
- 2020-12-03 WO PCT/EP2020/084430 patent/WO2021110816A1/en not_active Ceased
- 2020-12-03 EP EP20816198.4A patent/EP4069733A1/en active Pending
- 2020-12-03 KR KR1020227022860A patent/KR20220122652A/ko not_active Withdrawn
- 2020-12-04 US US17/111,689 patent/US20210188963A1/en not_active Abandoned
- 2020-12-04 TW TW109142821A patent/TW202134269A/zh unknown
-
2021
- 2021-10-15 US US17/502,332 patent/US11332525B2/en active Active
-
2022
- 2022-04-25 US US17/727,868 patent/US20220372128A1/en active Pending
- 2022-04-25 US US17/727,876 patent/US12528860B2/en active Active
- 2022-07-01 CO CONC2022/0009239A patent/CO2022009239A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220363747A1 (en) | 2022-11-17 |
| CN114981300A (zh) | 2022-08-30 |
| US11332525B2 (en) | 2022-05-17 |
| CO2022009239A2 (es) | 2022-07-29 |
| TW202134269A (zh) | 2021-09-16 |
| MX2022006880A (es) | 2022-07-11 |
| US20220064281A1 (en) | 2022-03-03 |
| JP2023505492A (ja) | 2023-02-09 |
| IL293561A (en) | 2022-08-01 |
| KR20220122652A (ko) | 2022-09-02 |
| AU2020396204A1 (en) | 2022-07-28 |
| US20220372128A1 (en) | 2022-11-24 |
| PH12022551214A1 (en) | 2023-10-09 |
| CN114981300B (zh) | 2025-10-31 |
| JP7657797B2 (ja) | 2025-04-07 |
| EP4069733A1 (en) | 2022-10-12 |
| WO2021110816A1 (en) | 2021-06-10 |
| US12528860B2 (en) | 2026-01-20 |
| CA3163877A1 (en) | 2021-06-10 |
| US20210188963A1 (en) | 2021-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022009799A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23 | |
| BR112023005273A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a il-13 e ox40l | |
| CO2018009533A2 (es) | Conjugados de amanitina | |
| CY1125141T1 (el) | Εισαγωγη μεταβλητων θραυσματων αντισωματων και τροποποιημενοι τομεις α1-α2 των συνδετων nkg2d | |
| AR120698A1 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp | |
| CO2019006565A2 (es) | Novedoso conjugado de amanitina | |
| UY36536A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| DOP2019000011A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| MX2023003630A (es) | Aglutinantes de albumina de suero mejorados. | |
| DOP2018000281A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
| MY208649A (en) | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp | |
| MX2022011935A (es) | Terapeuticos de anticuerpo que se unen a ctla4. | |
| BR112018005573A2 (pt) | ?polipeptídeos de ligação a cd3? | |
| BR112019022515A2 (pt) | Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos | |
| EA201892691A1 (ru) | Однодоменный белок, связывающий сывороточный альбумин | |
| CO2022008576A2 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα y ox40l | |
| BR112017022256A2 (pt) | conjugados de anticorpo-droga sítio-específicos | |
| EA201290123A1 (ru) | Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| BR112019005316A2 (pt) | anticorpos monoclonais para morte programada 1 (pd-1) | |
| BR112017020986A2 (pt) | proteínas de ligação recombinantes e seu uso | |
| MX2019003225A (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados. | |
| EA200970210A1 (ru) | Prlr-специфическое антитело и его применения | |
| MX2015011075A (es) | Peptidos terapeuticos. | |
| BR112017022252A2 (pt) | conjugados de anticorpo-droga sítio-específicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |